An anti-infective peptide that selectively modulates the innate immune response

Abstract

We show that an innate defense–regulator peptide (IDR-1) was protective in mouse models of infection with important Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus and Salmonella enterica serovar Typhimurium. When given from 48 h before to 6 h after infection, the peptide was effective by both local and systemic administration. Because protection by IDR-1 was prevented by in vivo depletion of monocytes and macrophages, but not neutrophils or B- and T-lymphocytes, we conclude that monocytes and macrophages are key effector cells. IDR-1 was not directly antimicrobial: gene and protein expression analysis in human and mouse monocytes and macrophages indicated that IDR-1, acting through mitogen-activated protein kinase and other signaling pathways, enhanced the levels of monocyte chemokines while reducing pro-inflammatory cytokine responses. To our knowledge, an innate defense regulator that counters infection by selective modulation of innate immunity without obvious toxicities has not been reported previously.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Efficacy of IDR-1 in bacterial infection models.
Figure 2: Lack of IDR-1 toxicity.
Figure 3: Selective stimulation of innate immunity by IDR-1.
Figure 4: Modulation of LPS–stimulated pro-inflammatory effects.
Figure 5: Confirmation of IDR-1 mechanism in vivo.
Figure 6: Proposed mechanism of action of IDR-1.

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. 1

    Theuretzbacher, U. & Toney, J.H. Nature's clarion call of antibacterial resistance: are we listening? Curr. Opin. Investigat. Drugs 7, 158–166 (2006).

    CAS  Google Scholar 

  2. 2

    Spellberg, B. et al. Trends in Antimicrobial Drug Development: Implications for the Future. Clin. Infect. Dis. 38, 1279–1286 (2004).

    CAS  Article  PubMed  Google Scholar 

  3. 3

    Finlay, B.B. & Hancock, R.E.W. Can innate immunity be enhanced to treat infections? Nat. Rev. Microbiol. 2, 497–504 (2004).

    CAS  Article  PubMed  Google Scholar 

  4. 4

    National Research Council Treating Infectious Diseases in a Microbial World: Report of Two Workshops. Washington, D.C.: The National Academies Press, (2005).

  5. 5

    O'Neill, L.A. How Toll-like receptors signal: what we know and what we don't know. Curr. Opin. Immunol. 18, 3–9 (2006).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Pasare, C. & Medzhitov, R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560, 11–18 (2005).

    CAS  Article  PubMed  Google Scholar 

  7. 7

    Tosi, M.F. Innate immune responses to infection. J. Allergy Clin. Immunol. 116, 241–249 (2005).

    CAS  Article  PubMed  Google Scholar 

  8. 8

    Martinon, F. & Tschoop, J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 26, 447–454 (2005).

    CAS  Article  PubMed  Google Scholar 

  9. 9

    Oppenheim, J.J. & Yang, D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359–365 (2005).

    CAS  Article  Google Scholar 

  10. 10

    Bowdish, D.M.E. et al. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77, 451–459 (2005).

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Mookherjee, N. et al. Modulation of the Toll-like receptor-mediated inflammatory response by the endogenous human host defence peptide LL-37. J. Immunol. 176, 2455–2464 (2006).

    CAS  Article  PubMed  Google Scholar 

  12. 12

    Niyonsaba, F. et al. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur. J. Immunol. 31, 1066–1075 (2001).

    CAS  Article  PubMed  Google Scholar 

  13. 13

    Lau, Y.E. et al. Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. Am. J. Respir. Cell Mol. Biol. 34, 399–409 (2006).

    CAS  Article  PubMed  Google Scholar 

  14. 14

    Bowdish, D.M.E., Davidson, D.J., Scott, M.G. & Hancock, R.E.W. Immunomodulatory activities of small host defence peptides. Antimicrob. Agents Chemother. 49, 1727–1732 (2005).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15

    Tsuji, M. et al. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models. Antimicrob. Agents Chemother. 47, 2507–2512 (2003).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16

    Gehlhar, K. et al. Characterization of modified allergen extracts by in vitro beta-hexosaminidase release from rat basophils. Int. Arch. Allergy Immunol. 136, 311–319 (2005).

    CAS  Article  PubMed  Google Scholar 

  17. 17

    Hanlon, M., Sturgill, T.W. & Sealy, L. ERK2- and p90(Rsk2)-dependent pathways regulate the CCAAT/enhancer-binding protein-beta interaction with serum response factor. J. Biol. Chem. 276, 38449–38456 (2001).

    CAS  Article  PubMed  Google Scholar 

  18. 18

    Marcinkowska, E. et al. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. Exp. Cell Res. 312, 2054–2065 (2006).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19

    Fessele, S. et al. Molecular and in silico characterization of a promoter module and C/EBP element that mediate LPS-induced RANTES/CCL5 expression in monocytic cells. FASEB J. 15, 577–579 (2001).

    CAS  Article  PubMed  Google Scholar 

  20. 20

    Williams, S.C. et al. C/EBP is a myeloid-specific activator of cytokine, chemokine, and macrophage-colony-stimulating factor receptor genes. J. Biol. Chem. 273, 13493–13501 (1998).

    CAS  Article  PubMed  Google Scholar 

  21. 21

    Kubota, T. et al. Representational difference analysis using myeloid cells from C/EBP epsilon deletional mice. Blood 96, 3953–3957 (2000).

    CAS  PubMed  Google Scholar 

  22. 22

    Prins, J.M. et al. Release of tumor necrosis factor and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect. Immun. 63, 2236–2242 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23

    Zisman, D.A. et al. Standiford TJ. MCP-1 protects mice in lethal endotoxemia. J. Clin. Invest. 99, 2832–2836 (1997).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24

    Cavaillon, J.M., Adib-Conquy, M., Fitting, C., Adrie, C. & Payen, D. Cytokine cascade in sepsis. Scand. J. Infect. Dis. 35, 535–544 (2003).

    CAS  Article  PubMed  Google Scholar 

  25. 25

    Brenner, S. et al. cAMP-induced Interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation. J. Biol. Chem. 278, 5597–5604 (2003).

    CAS  Article  PubMed  Google Scholar 

  26. 26

    Zwergal, A. et al. C/EBPbeta blocks p65 phosphorylation and thereby NFκB-mediated transcription in TNF-tolerant Cells. J. Immunol. 177, 665–672 (2006).

    CAS  Article  PubMed  Google Scholar 

  27. 27

    Cote, C.K., Van Rooijen, N. & Welkos, S.L. Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect. Immun. 74, 469–480 (2006).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. 28

    Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29

    Hokamp, K. et al. ArrayPipe: a flexible processing pipeline for microarray data. Nucleic Acids Res. 32 (Web Server issue), W457–459 (2004).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge financial support from the Foundation for the National Institutes of Health and Canadian Institutes for Health Research through the Grand Challenges in Global Health Initiative, and from Genome BC for the Pathogenomics of Innate Immunity research program. R.E.W.H. is the recipient of a Canada Research Chair. M.G.S. was the recipient of a Natural Sciences and Engineering Research Council Industrial Fellowship. The authors gratefully acknowledge the technical expertise of Reza Falsafi.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Robert E W Hancock.

Ethics declarations

Competing interests

Several of the authors (M.G.S., E.D.,N.G., A.T., A.W., K.L., O.D., M.M.G.,J.R.N.) are or have been employees of Inimex Pharmaceuticals, which is developing Innate Defence Regulators as human therapeutics against bacterial infections and fever, while R.E.W.H. and B.F. are consultants and members of the scientific advisory board of Inimex Pharmaceuticals.

Supplementary information

Supplementary Fig. 1

Combination with Antibiotics (PDF 18 kb)

Supplementary Fig. 2

Non-local activity of IDR–1 in Thigh Model (PDF 28 kb)

Supplementary Fig. 3

Protection in T/B cell Depleted animals (PDF 151 kb)

Supplementary Fig. 4

Transcriptional profiling of genes differentially expressed by IDR–1 in CD14 positive monocytes (PDF 47 kb)

Supplementary Fig. 5

Activation of C/EBPβ by IDR–1 (PDF 64 kb)

Supplementary Fig. 6

Differential activation of NFκB by LPS, CpG oligonucleotide and IDR-1 (PDF 37 kb)

Supplementary Fig. 7

IDR-1 does not block LPS binding to LBP (PDF 46 kb)

Supplementary Table 1

Representative genes from the microarray analysis (DOC 393 kb)

Supplementary Methods (DOC 43 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scott, M., Dullaghan, E., Mookherjee, N. et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 25, 465–472 (2007). https://doi.org/10.1038/nbt1288

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing